D'ALESSIO, ANTONIO
 Distribuzione geografica
Continente #
AS - Asia 140
EU - Europa 102
NA - Nord America 22
Totale 264
Nazione #
SG - Singapore 71
HK - Hong Kong 68
RU - Federazione Russa 41
IT - Italia 19
DE - Germania 18
US - Stati Uniti d'America 18
AT - Austria 7
NL - Olanda 5
CA - Canada 4
UA - Ucraina 3
CH - Svizzera 2
FI - Finlandia 2
GB - Regno Unito 2
LT - Lituania 2
FR - Francia 1
ID - Indonesia 1
Totale 264
Città #
Hong Kong 66
Singapore 15
Moscow 9
Falkenstein 7
Novara 7
Assago 4
Toronto 3
Vienna 3
Frankfurt am Main 2
Genoa 2
Helsinki 2
Nuremberg 2
Sona 2
Zurich 2
Amsterdam 1
Islington 1
Jakarta 1
London 1
Ottawa 1
Palermo 1
Paris 1
Totale 133
Nome #
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 27
New Scenarios in Liver Transplantation for Hepatocellular Carcinoma 22
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 19
The price and value of therapeutic synergy in liver cancer 18
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 15
Diabetes and Immune Checkpoint Inhibitors—Response 15
Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma 14
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 14
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 13
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 12
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 12
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events 12
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 12
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 11
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction-Reply 11
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study 11
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 11
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison 10
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer 10
Immunotherapy at all stages of hepatocellular carcinoma 10
Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma 10
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 8
Totale 297
Categoria #
all - tutte 1.348
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.348


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025297 5 0 5 2 4 7 45 106 98 25 0 0
Totale 297